Trial · NCT05301517
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hemoglobin (Hb) Level From Baseline to the Level Averaged Over Weeks 9-13 | Baseline, Weeks 9 through 13 | Hb levels measured from Weeks 9 through 13 will be averaged in order to provide a single measure for comparison to the baseline Hb levels. |
| Secondary | Percentage of Participants who Achieve a ≥10 Grams (g)/Liter (L) Increase in Hb From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Percentage of Participants who Require Red Blood Cell (RBC) Transfusion or Hb <60 g/L or with any Hb< 60 g/L From Week 5 Through Week 13 | Week 5 through Week 13 | |
| Secondary | Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale Score Averaged Over Weeks 9-13 | Baseline, Weeks 9 through 13 | FACT-An subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score. |
| Secondary | Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Subscale Score Averaged Over Weeks 9-13 | Baseline, Weeks 9 through 13 | FACIT-F subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score. |
| Secondary | Percentage of Participants who Require Dose Reduction or a Dose-Hold of Chemotherapy Due to Anemia | Baseline through Week 13 | |
| Secondary | Change in Hb From Baseline up to 4 Weeks After the Last Dose of Chemotherapy During the Treatment Period | Baseline up to 4 weeks after the last dose of chemotherapy (up to Week 16) | |
| Secondary | Change in Hb From Baseline Through Week 9 | Baseline through Week 9 | |
| Secondary | Change in Hb From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Percentage of Participants who Achieve a ≥ 15 g/L Increase in Hb From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Percentage of Participants who Achieve Hb Levels ≥ 110 g/L From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Percentage of Participants who Achieve an Increase in Hb of 15 g/L or Attaining a Hb of 110 g/L From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Time to First RBC Transfusion | Baseline up to Week 13 | |
| Secondary | Percentage of Participants Requiring 1 or More RBC Transfusion | Baseline up to Week 13 | |
| Secondary | Number of RBC Transfusions Adjusted for Exposure From Baseline Through Week 13 | Baseline through Week 13 | |
| Secondary | Percentage of Participants who Require RBC Transfusion as Medical Intervention and/or Erythropoiesis-Stimulating Agent (ESA) as a Rescue Agent | Baseline through Week 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05301517/registered